SeekingAlpha · Feb 18, 2026
OTC · MDRX
Veradigm Inc.
Healthcare · Medical - Healthcare Information Services
$4.95
Down-$0.00 (-0.08%)
Updated Aug 21, 2026, 10:22 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 823.68M
- P/E ratio
- -7.23
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 450
- Avg. volume
- 109.14K
Price performance
MDRX price history
1M range · 0 trading sessions · Daily adjusted prices
MDRX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest MDRX news
The latest Smart Investors Daily articles mentioning MDRX.
Stock researchCompany · Overview
MDRX research
Overview
Company profile and research snapshot.
Company profile
VERADIGM INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $16.17
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 31, 2025 | Stephens & Co. | Equal-Weight | — |
| May 28, 2024 | TD Cowen | Buy | — |
| Mar 19, 2024 | Deutsche Bank | Hold | — |
| Jan 19, 2024 | RBC Capital | Outperform | — |
| Jan 3, 2024 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
businesswire.com · Nov 17, 2025
Veradigm Launches Enhanced Ambient Scribe Capabilities
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced enhancements to the artificial intelligence (AI) enhanced Ambient Scribe solution for Veradigm EHR customers. This milestone reflects Veradigm's commitment to delivering evolved AI solutions that improve clinical documentation, support clinical decision-making, and enhance patient care. Since its launch last year, Veradigm Ambient Scribe has developed into a robus.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.

